{
    "clinical_study": {
        "@rank": "45457", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the potential of nutritional docosahexaenoic acid (DHA) supplementation to\n      normalize the level of DHA in red blood cells, and to retard the progression of visual\n      function loss in patients with early stage X-linked retinitis pigmentosa."
        }, 
        "brief_title": "Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa", 
        "condition": "Retinitis Pigmentosa", 
        "condition_browse": {
            "mesh_term": [
                "Retinitis", 
                "Retinitis Pigmentosa"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, parallel, double blind study. Patients receive 2 gel\n      capsules per day of either docosahexaenoic acid (DHA) enriched oil or a placebo oil.  Oral\n      DHA supplementation continues daily for 3 years.\n\n      All patients are followed every 6 months for the 3 year duration of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of X-linked retinitis pigmentosa\n\n        Early stage disease Sufficient cone function determined by recordable ERG (30 Hz\n        amplitude; greater than 0.32 microvolts) Visual fields greater than 20 degrees Sufficient\n        rod function (greater than 3.0 microvolts amplitude)\n\n        Media clarity sufficient for fundus photography\n\n        --Prior/Concurrent Therapy--\n\n        No concurrent use of anticoagulant medication\n\n        --Patient Characteristics--\n\n          -  No chronic metabolic disease that may interfere with fatty acid metabolism\n\n          -  No bleeding of clinical significance"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "46", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004827", 
            "org_study_id": "199/13351", 
            "secondary_id": "RFS-FDR001232"
        }, 
        "intervention": {
            "intervention_name": "docosahexaenoic acid", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "ophthalmologic disorders", 
            "rare disease", 
            "retinitis pigmentosa"
        ], 
        "lastchanged_date": "May 15, 2009", 
        "overall_official": {
            "affiliation": "Retina Foundation of the Southwest", 
            "last_name": "Dennis R. Hoffman", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004827"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Retina Foundation of the Southwest", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "March 1996", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1998"
    }, 
    "geocoordinates": {}
}